ZIMVIE INC Stock Price, News & Analysis

ZimVie Inc. announced the French government's approval for Mobi-C Cervical Disc reimbursement, enhancing access to this treatment in both public and private sectors as of April 3, 2023. Furthermore, the product received a top quality rating of 10A* from the Orthopaedic Data Evaluation Panel in the UK, indicating strong clinical evidence supporting its performance. Mobi-C, a leading cervical disc replacement device, has been in use since 2004, and its reimbursement is expected to increase adoption among surgeons, as noted by Dr. Thierry Dufour in Paris. This approval addresses financial barriers and underscores the product's credibility in the medical community.

ZimVie Inc. (Nasdaq: ZIMV) announced the publication of a study in The International Journal of Oral & Maxillofacial Implants, highlighting the favorable properties of its Puros Cancellous Particulate Allograft. This allograft exhibited a collagen microstructure and surface area 100 times greater than freeze-dried allografts, leading to a significantly higher response from mesenchymal stromal cells (hBMSC) in vitro. ZimVie’s Puros portfolio has been utilized for over 20 years, backed by over 300 peer-reviewed publications, establishing it as a leading choice in dental implants.

ZimVie Inc. (Nasdaq: ZIMV) announces that Highmark and BCBS North Dakota have deemed the Tether™ device as medically necessary for treating pediatric scoliosis. Effective January 30, 2023, and March 6, 2023, respectively, the new policies expand eligibility for vertebral body tethering (VBT) to over 4 million and 280,000 patients. The Tether™ is the only FDA-approved device for VBT, with over 1,300 applications since its humanitarian device exemption in August 2019. Experts indicate these developments highlight advancements in VBT technology, allowing more children to access crucial treatment within their growth window.

ZimVie Inc. (Nasdaq: ZIMV) reported its FY 2022 financial results, with third-party net sales of $909.5 million, reflecting a 9.8% decline compared to FY 2021. The company recorded a net loss of ($63.9 million) and a net loss margin of (7.0%). Adjusted net income rose to $47.9 million with adjusted diluted EPS at $1.84. The fourth quarter saw net sales of $228.2 million, down 12.4% year-over-year. Key developments included new product launches, an expanded policy decision affecting 4+ million lives, and a successful ERP transition. Guidance for FY 2023 predicts net sales between $825 million and $850 million.

ZimVie Inc. (Nasdaq: ZIMV) announced advancements in its digital dentistry platform with the launch of two new modules: the RealGUIDE CAD and FULL SUITE. The CAD module enhances restorative workflows with advanced design capabilities, allowing users to create complex dental structures easily. The FULL SUITE integrates existing modules into a comprehensive system, facilitating collaborative implant planning and guided surgery. These innovations will debut at LMT Lab Day in Chicago and expand to Europe at the International Dental Show next month. This strategic enhancement aims to streamline operations for dental practices and support successful patient outcomes.

ZimVie Inc. (Nasdaq: ZIMV) announced it will report its financial results for the fourth quarter and full year 2022 on March 1, 2023, after market close. A conference call will follow at 4:30 p.m. Eastern Time. Interested parties can register for the call. ZimVie specializes in dental and spine markets and became an independent entity in March 2022, focusing on its product portfolio to serve customers in over 70 countries.

ZimVie Inc. (Nasdaq: ZIMV) announced a significant milestone, with over 200,000 Mobi-C Cervical Discs implanted globally since its FDA approval in 2013 for cervical disc replacement. This achievement aligns with the ten-year anniversary of the device's FDA clearance, which marked its superiority over fusion surgeries at the seven-year mark, and continued patient-reported outcomes at ten years. ZimVie highlights this success as part of its 'Year of Mobi-C' initiative, reinforcing its commitment to advancing cervical disc technology and improving patient care.

ZimVie Inc. (Nasdaq: ZIMV), a leader in life sciences within the dental and spine markets, will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco. CEO Vafa Jamali is scheduled to speak on January 11, 2023, at 3:00 p.m. PT. The presentation will be accessible via a live and archived webcast. Founded in March 2022 as a spin-off from Zimmer Biomet, ZimVie provides a wide range of dental and spine solutions across over 70 countries, focusing on product innovation and clinical evidence.

ZimVie Inc. (Nasdaq: ZIMV) reported third quarter 2022 financial results with third party net sales of $213.3 million, a decrease of 10.6% year-over-year. Net income reached $0.8 million, compared to a net loss of $30.2 million in Q3 2021. Adjusted diluted EPS was $0.49. The dental segment saw a slight decline of 3.9%, while the spine segment dropped 16.4%, influenced by market exits and competitive pressures. Cash reserves were $116.0 million. The company reaffirmed full-year guidance for net sales of $915 to $930 million and adjusted EPS of $1.80 to $2.00.